• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    8/7/24 4:10:55 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VCNX alert in real time by email
    SC 13D/A 1 d862054dsc13da.htm SC 13D/A SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Amendment No. 11)

    Under the Securities Exchange Act of 1934

     

     

    VACCINEX, INC.

    (Name of Issuer)

    Common Stock, Par Value $0.0001 per share

    (Title of Class of Securities)

    918640 202

    (CUSIP Number)

    Thomas J. Rice

    Baker & McKenzie LLP

    452 Fifth Avenue

    New York NY 10018

    (212) 626-4100

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 5, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 918640 202

     

     1.    

     Names of Reporting Persons

     

     FCMI PARENT CO.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     NOVA SCOTIA, CANADA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     -0-

        8.   

     Shared Voting Power

     

     780,704

        9.   

     Sole Dispositive Power

     

     -0-

       10.   

     Shared Dispositive Power

     

     780,704

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     780,704

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ☒

     

     See Item 5.

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     45.2%

    14.  

     Type of Reporting Person

     

     CO

     

    2


    CUSIP No. 918640 202

     

     1.    

     Names of Reporting Persons

     

     PAN ATLANTIC HOLDINGS LTD.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     BARBADOS

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     -0-

        8.   

     Shared Voting Power

     

     180

        9.   

     Sole Dispositive Power

     

     -0-

       10.   

     Shared Dispositive Power

     

     180

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     180

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0.01%

    14.  

     Type of Reporting Person

     

     CO

     

    3


    CUSIP No. 918640 202

     

     1.   

     Names of Reporting Persons

     

     ALBERT D. FRIEDBERG

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF, PF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     CANADA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     2,094

        8.   

     Shared Voting Power

     

     797,428

        9.   

     Sole Dispositive Power

     

     2,094

       10.   

     Shared Dispositive Power

     

     797,428

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     799,522

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ☒

     

     See Item 5.

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     46.3%

    14.  

     Type of Reporting Person

     

     IN

     

    4


    CUSIP No. 918640 202

     

     1.   

     Names of Reporting Persons

     

     FRIEDBERG GLOBAL-MACRO HEDGE FUND LTD.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     CAYMAN ISLANDS

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     -0-

        8.   

     Shared Voting Power

     

     16,724

        9.   

     Sole Dispositive Power

     

     -0-

       10.   

     Shared Dispositive Power

     

     16,724

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     16,724

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     1.0%

    14.  

     Type of Reporting Person

     

     CO

     

    5


    CUSIP No. 918640 202 

     

     1.    

     Names of Reporting Persons

     

     FRIEDBERG MERCANTILE GROUP LTD.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     CANADA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     -0-

        8.   

     Shared Voting Power

     

     16,724

        9.   

     Sole Dispositive Power

     

     -0-

       10.   

     Shared Dispositive Power

     

     16,724

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     16,724

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     1.0%

    14.  

     Type of Reporting Person

     

     CO

     

    6


    Item 1.

    Security and Issuer

    The Statement on Schedule 13D filed on August 24, 2018 (the “Statement”) by FCMI Parent Co. (“FCMI Parent”), FCMI Financial Corporation (“FCMI”), Pan Atlantic Bank and Trust Limited, Friedberg Global-Macro Hedge Fund Ltd. (“G-M Fund”), Friedberg Mercantile Group, Ltd. (“FMG”) and Albert D. Friedberg (collectively, the “Filing Persons” and each, individually, a “Filing Person”), relating to the common stock, par value $0.0001 per share (the “Common Stock”) of Vaccinex, Inc., a Delaware corporation (the “Issuer”), as amended by Amendment No. 1 to the Statement filed July 31, 2019, Amendment No. 2 to the Statement filed January 27, 2020, Amendment No. 3 to the Statement filed July 16, 2020, Amendment No. 4 to the Statement filed February 14, 2022, Amendment No. 5 to the Statement filed November 29, 2022, Amendment No. 6 to the Statement filed April 5, 2023, Amendment No. 7 filed May 25, 2023, Amendment No. 8 filed October 18, 2023, Amendment No. 9 filed February 13, 2024 and Amendment No. 10 filed August 1, 2024, is hereby further amended with respect to the matters set forth below in this Amendment. Capitalized terms not otherwise defined herein have the meanings set forth in the Statement.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    Item 3 of the Statement is hereby amended by the addition of the following information:

    On August 5, 2024, FCMI Parent and Mr. Friedberg acquired beneficial ownership of 3,653 shares of Common Stock through the following open-market purchases made by FCMI Parent:

     

    Number of shares purchased

       Price per share ($)      Amount paid ($)  

    3,653

         4.60        16,803.80  

    On August 6, 2024, FCMI Parent and Mr. Friedberg acquired beneficial ownership of 2,753 shares of Common Stock through the following open-market purchases made by FCMI Parent:

     

    Number of shares purchased

       Price per share ($)      Amount paid ($)  

    2,753

         4.92        13,544.76  

     

    Item 4.

    Purpose of Transaction.

    Item 4 of the Statement is hereby amended by the addition of the following information:

    The aggregate total of 6,406 shares of Common Stock described in Item 3 were purchased by FCMI Parent for investment purposes. The information provided in Item 3 with respect to the 6,406 shares of Common Stock purchased is incorporated by reference herein.

    The Filing Persons do not have any present intention or arrangements to acquire additional shares of Common Stock. The Filing Persons do not have any present intention to sell any Common Stock that will be included in such Registration Statement, and note that their ability to effect dispositions of Common Stock, other than pursuant to the Registration Statement, or prior shelf registration statements filed by the Company, may be limited by their status as “affiliates” of the Issuer.

    Subject to the foregoing, the Filing Persons reserve the right to take, in the future, such actions with respect to their investment in the Issuer as they deem appropriate. Except as described herein, the Filing Persons do not have any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Filing Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

     

    Item 5.

    Interest in Securities of the Issuer.

    The table in Item 5 of the Statement showing beneficial ownership of the Issuer’s Common Stock by each of the Filing Persons, together with the introductory paragraph to such table and the paragraph immediately following such table, as well as the information regarding ownership of the Issuer’s Common Stock by the directors and officers of the Filing Persons, are hereby amended and restated in their entirety as follows:

    On the date of this Schedule 13D (Amendment No. 11), the Filing Persons are the beneficial owners of a total of 799,522 shares of the Issuer’s Common Stock, representing 46.3% of the Issuer’s outstanding Common Stock. Each Filing Person’s direct ownership and beneficial ownership has been computed as a percentage of 1,727,700 shares outstanding or deemed outstanding as of August 7, 2024 plus any shares that may be acquired pursuant to presently exercisable warrants. The following table shows the number of shares of Common Stock and the percentage of the Issuer’s Common Stock directly owned and beneficially owned by each Filing Person:

     

     

    7


    Name

       Shares
    Directly
    Owned
         Percentage
    Directly
    Owned
        Shares
    Owned
    Beneficially
         Percentage
    Owned
    Beneficially
     

    PAHL

         180        0.01 %      180 1       0.01 %1 

    FCMI Parent

         780,524        45.2 %      780,704 2       45.2 %3 

    G-M Fund

         16,724        1.0 %      16,724 4       1.0 %4 

    FMG

         -0-        -0- %      16,724 4       1.0 %4 

    Albert Friedberg

         2,094        0.1 %      799,522 5       46.3 %5 

     

    1 

    All such shares are owned of record directly by PAHL. See “Beneficial Ownership of Shares Under PAHL Pledge Arrangements” in Item 5 of the original Statement filed on August 24, 2018.

    2 

    Includes the following: (i) 780,524 shares owned directly by FCMI Parent; and (ii) 180 shares owned directly by PAHL. FCMI Parent will not have the right to exercise any Warrants to the extent that, after giving effect to the issuance of the common stock resulting from such exercise, FCMI Parent together with its affiliates and certain other parties as set forth in Warrant, would beneficially own more than 39.99% of the outstanding shares of common stock immediately after giving effect to the issuance of shares issuable upon exercise of the Warrant. Accordingly, the shares reported on the table above as beneficially owned by FCMI Parent do not include 435,471 presently exercisable warrants that would bring FCMI Parent in excess of its ownership limit.

    3 

    The percentage ownership does not include amounts in excess of the ownership limit for FCMI Parent described above in footnote 2 to this table.

    4 

    All such 16,724 shares are owned by G-M Fund. Voting and dispositive power over the shares held by G-M Fund are exercisable by FMG, the investment manager of G-M Fund.

    5 

    Includes the following: (i) 180 shares owned directly by PAHL; (ii) 780,524 shares owned directly by FCMI Parent; (iii) 16,724 shares owned directly by G-M Fund; and (iv) 2,094 shares owned directly by Mr. Friedberg.

    All shares reported as beneficially owned by the Filing Persons are presently outstanding. Mr. Friedberg, directly and through his control over FCMI Parent shares held by members of his family and trusts for the benefit of members of his family, may be considered the beneficial owner of all of the Common Stock beneficially owned by FCMI Parent. By virtue of his control of FCMI Parent, Mr. Friedberg also may be deemed to possess voting and dispositive power over the shares owned directly by its wholly-owned subsidiary, PAHL. By virtue of his control of FMG, which exercises voting and dispositive power over the shares owned directly by G-M Fund, Mr. Friedberg also may be deemed to possess voting and dispositive power over the shares owned directly by G-M Fund.

    As of August 7, 2024, Enrique Zauderer, Vice President and a Director of FMG and Mr. Daniel A. Gordon, Vice President, Chief Compliance Officer and a Director of FMG, are the beneficial owners of 1,114 shares and 885 shares, respectively, of the Issuer’s Common Stock.

    Except for (i) the Common Stock beneficially owned by Mr. Friedberg, (ii) the Common Stock beneficially owned by each of Messrs. Zauderer and Gordon, to the knowledge of the Filing Persons, none of the directors or officers of any of the Filing Persons beneficially owns any Common Stock.

    In addition to FCMI Parent’s purchase of 3,653 and 2,753 shares of Common Stock on August 5, 2024 and August 6, 2024, respectively, FCMI Parent effected the following transactions in the 60 days preceding the filing of this Section 13D (Amendment No. 11):

    August 1, 2024:

     

    Number of shares purchased

       Price per share ($)      Amount paid ($)  

    11,703

         4.72        55,238.16  

     

    8


    July 31, 2024:

     

    Number of shares purchased

       Price per share ($)      Amount paid ($)  

    200,000

         6.15 *       1,230,260  

     

    *

    Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $7.40, inclusive.

     

    9


    Signatures

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: August 7, 2024

     

    FCMI PARENT CO.
    By:  

    /s/ Dan Scheiner

    Name:   Dan Scheiner
    Title:   Vice President
    PAN ATLANTIC HOLDINGS LTD.
    By:  

    /s/ Mary Ellen Bourque

    Name:   Mary Ellen Bourque
    Title:   Director
    FRIEDBERG GLOBAL-MACRO HEDGE FUND LTD.
    By:  

    /s/ Albert D. Friedberg

    Name:   Albert D. Friedberg
    Title:   Director
    FRIEDBERG MERCANTILE GROUP LTD.
    By:  

    /s/ Albert D. Friedberg

    Name:   Albert D. Friedberg
    Title:   Director
    ALBERT D. FRIEDBERG, individually
     

    /s/ Albert D. Friedberg

    Name:   Albert D. Friedberg

     

    10

    Get the next $VCNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VCNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Albert bought $451 worth of shares (100 units at $4.51) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/13/24 4:30:45 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $30,349 worth of shares (6,406 units at $4.74) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/7/24 4:04:52 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $55,238 worth of shares (11,703 units at $4.72) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/2/24 4:05:32 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    SEC Filings

    See more
    • SEC Form 10-K filed by Vaccinex Inc.

      10-K - VACCINEX, INC. (0001205922) (Filer)

      4/15/25 5:12:41 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Vaccinex Inc.

      NT 10-K - VACCINEX, INC. (0001205922) (Filer)

      4/1/25 7:01:02 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Vaccinex Inc.

      15-12G - VACCINEX, INC. (0001205922) (Filer)

      3/27/25 8:24:58 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Albert was granted 30,756 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:06:19 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice was granted 46,153 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:05:50 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice exercised 113,650 shares at a strike of $5.64 (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      9/20/24 4:14:02 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

      ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO)

      5/27/25 8:45:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

      Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne

      4/21/25 8:45:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

      ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the "Common Stock"), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to

      3/7/25 5:15:00 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      11/18/24 4:15:28 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vaccinex Inc.

      SC 13G - VACCINEX, INC. (0001205922) (Subject)

      11/14/24 3:39:20 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      9/20/24 5:15:25 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care